On July 14, Asymchem Laboratories (06821.HK) rose 5.01% in regular trading, trading at HK$127.2/share, with turnover of HK$48.50 million.
On the news front, multiple bullish catalysts continued to drive sentiment. Nomura Securities raised its target price on Asymchem from HK$115.43 to HK$131.48, maintaining a Buy rating. The core thesis centers on the rapid global expansion of GLP-1 receptor agonists, which is expected to sustainably benefit the CXO supply chain. Meanwhile, JPMorgan Chase increased its position by 143,800 shares on July 7 at approximately HK$111.63 per share, lifting its stake to 9.17%, with total investment of approximately HK$16.05 million.
The current share price has reached the vicinity of Nomura's new target price, with institutional bullish signals and foreign capital accumulation creating resonance that extends market buying momentum. It is worth noting that Schroders PLC reduced its holding by 131,000 shares on July 9, providing some counterbalance to the positive flows.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments